Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

NCT01740297 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Talimogene laherparepvec
DRUG: Ipilimumab

Sponsor

Amgen